Pipeline

Overview

Differentiated pipeline established through our proprietary engine

Synedgen is well-positioned to lead the industry in the advancement of modified polysaccharides for therapeutic use. We are aggressively moving toward the clinic with numerous programs in the research or pre-clinical development stages.

Improving lives by changing the progression of disease

Our pipeline includes compounds with the potential to change the progression of disease in the following ways:

  • Address complications in cystic fibrosis that currently have limited treatment options.
  • Reduce damage and inflammation due to chemical, radiological or physical damage.
  • Disrupt biofilms and loosen mucus in the lungs and GI tract.
  • Target the host-pathogen interface utilizing novel mechanisms to reduce the challenge of antibiotic resistance.
  • Provide a barrier to infection for faster and improved wound healing.

Synedgen has licensed its Glycomics Technology for Cystic Fibrosis and other pulmonary conditions to Synspira.

 SEE HOW SYNSPIRA IS USING ITS LICENSE TO THE PULMONARY TECHNOLOGIES OF OUR GLYCOMICS PLATFORM

SYGN305: Synedgen is developing SYGN305 for treating complications to the bowel associated with radiation therapies, a side effect of cancer treatments that breaks down the epithelial cells lining the GI tract, leaving the mucosal tissue open to ulceration and infection. Radiation Proctitis, inflammation of the lining of the rectum and other areas of the GI tract, are toxicities that limit GI radiation to effectively reduce tumors. SYGN305 is designed to reduce radiation GI toxicity to allow for greater therapeutic index to aggressively treat tumors of the abdominal and GI tract by reducing GI toxicities.

SYGN399: Acute damage and inflammation in gastrointestinal mucosa is often caused by chemical or radiative damage. In the case of unexpected radiation due to nuclear threats or dirty bombs, this damage is similar to that seen in inflammatory GI diseases such as Crohn’s disease and IBD, which result in chronic and painful lesions. SYGN399 has been shown in animal models to reduce chemical or radiation-induced mortality caused by disruption of mucosal defenses and bacterial translocation resulting in sepsis.

SYGN303: Synedgen is developing SYGN303 as a potential treatment for distal intestinal obstructive syndrome (DIOS), in which thick mucus causes blockage in the intestine of patients with cystic fibrosis. DIOS is a GI complication for which there are no targeted or approved drugs for CF patients.

SYGN313: Few safe and effective therapies are available for treating inflammatory diseases of the GI tract. Synedgen is developing SYGN313 for both acute and chronic inflammation of the GI tract. SYGN313 has shown improved efficacy in models of both Crohn’s disease and inflammatory bowel disease (IBD) over standard of care, with evidence of the ability to reduce inflammation at the local level. SYGN313 works from the “outside-in”, reducing damage and improving the healing of GI lesions and inflammation

SYGN309: Excessive use of antibiotics can disrupt the normal flora, leaving a damaged, inflamed GI tract with an unbalanced commensal flora. Synedgen is developing SYGN309 to treat GI Infections without disrupting the normal flora and restoring a normal commensal flora.